ALKERMES | ALKS - Ordinary Share Capital


ALKERMES reported $166.46M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
ALKERMES USD 166.46M 855K Mar/2026
Amgen USD 540M 1000K Mar/2026
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.27M 969K Mar/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Coherus Biosciences USD 121.16M 4.92M Dec/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Gilead Sciences USD 1.24B 1000K Mar/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Ionis Pharmaceuticals USD 165.9M 3.93M Mar/2026
J&J USD 2.41B 1.35M Mar/2026
Malin Corporation EUR 200K 0 Dec/2024
Merck USD 2.47B 12.72M Dec/2025
Minerva Neurosciences USD 1000 0 Sep/2024
Nektar Therapeutics USD 20.38M 20.36M Dec/2025
Neurocrine Biosciences USD 100.6M 500K Mar/2026
Otsuka Holdings JPY 527.31M 824K Mar/2026
Ovoca Bio EUR 29.49M 18.43M Jun/2025
Pfizer USD 5.7B 13M Mar/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Vertex Pharmaceuticals USD 254.2M 200K Mar/2026